HDAC6 and systemic lupus erythematosus: HDAC6 inhibition has shown efficiency in multiple preclinical models of inflammatory and autoimmune diseases, including IBD [81,82,83], RA [84,85], systemic lupus erythematosus (SLE) [78,86], multiple sclerosis [87], lung inflammatory diseases [88,89], allograft rejection [90], skin inflammatory diseases [91], sepsis [92], and acute liver injury [93].